Pfizer has become the first pharmaceutical company to agree to the Trump administration’s most-favored nation (MFN) drug pricing policy, committing to price its products in the U.S. in line with prices in comparable developed countries. The agreement includes launching a direct-to-consumer online platform, TrumpRX, offering discounted medications averaging over 50% off list prices. While the policy aims to lower drug costs, concerns remain about its impact on U.S. revenue and potential price increases overseas. Other pharmaceutical companies are expected to follow Pfizer’s lead in adopting similar pricing strategies as part of the administration’s broader initiative to bring fairness to drug pricing.